DDrare: Database of Drug Development for Rare Diseases

206. 脆弱X症候群
［臨床試験数：98，薬物数：73（DrugBank：27），標的遺伝子数：46，標的パスウェイ数：57］

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-flumazenil; 18F-FTC-146; ACIDUM ASCORBICUM D6; AF056; AFQ056; AZD7325; AZD7325 (High-Dose); AZD7325 (Low-Dose); Acamprosate; Acetate; Acidum ascorbicum; Alpha-tocopherol; Ampalex; Arbaclofen; Aripiprazole; Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E); Ascorbic acid; BPN14770; CBD; CCD 1042, MD 9150000, Mepalon 1042, SPT316; CX516; CX516 (Ampalex®); Donepezil; EGCG; EGCG FontUp; Flumazenil; Fluoxetin; GANAXOLONE; Gaboxadol; Ganaxolone; Lovastatin; Lovastatin, then Minocycline/Lovastatin; MG01CI extended-release tablet; MGlu5 antagonist; Mavoglurant; Metformin; Methylphenidate; Methylphenidate, fluoxetin, risperidone; Minocycline; Minocycline hydrochloride; Minocycline, then Minocycline/Lovastatin; NNZ-2566; NPL-2009; OV101; OV101 (gaboxadol); Other: Biological samples; Other: Cognitive training; Other: Language Intervention; Other: MRI; Oxytocin; Oxytocin 24IU; Oxytocin 48IU; RO4917523; RO4917523 0.5 mg; RO4917523 1.5 mg; Riluzole; Risperidone; Ro 491-7523/F18; Ro 491-7523/F19; STX107; STX209; Sertraline; Sugar pill; TOCOPHERYL ACETATE; Tocopherol; Tocopheryl acetate; Vitamin C; Vitamin C 10mg/Kg Vitamin E 10 mg/Kg; Vitamin E; ZYN002 - CBD Transdermal Gel; [18F]FPEB; [18F]FPEB PET imaging; [18F]flumazenil

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04141163 (ClinicalTrials.gov)	October 29, 2019	24/10/2019	Metformin in Patients With Fragile X	A Parallel Group Design Randomized Double-Blind Trial of Metformin Treatment in Patients With Fragile X Syndrome on Safety and Effects on Cognition, Anxiety, Attention and Biomarkers	Fragile X Syndrome	Drug: Metformin;Drug: Placebo oral tablet	Rowan University	FRAXA Research Foundation;University of Pennsylvania	Recruiting	18 Years	50 Years	Male	40	Phase 1;Phase 2	United States
2	NCT03862950 (ClinicalTrials.gov)	May 24, 2019	26/2/2019	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)	A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)	Fragile X Syndrome;Fragile X Mental Retardation Syndrome;Mental Retardation, X-Linked;Genetic Diseases, X-Linked;Trinucleotide Repeat Expansion;Fra(X) Syndrome;Intellectual Disability;FXS;Neurobehavioral Manifestations;Sex Chromosome Disorders	Drug: Placebo Medication;Drug: Metformin	University of Alberta	St. Justine's Hospital	Recruiting	6 Years	25 Years	All	120	Phase 2	Canada
3	NCT03722290 (ClinicalTrials.gov)	September 1, 2018	24/10/2018	Metformin in Children and Adults With Fragile X Syndrome	Evaluate the Efficacy and Safety of Metformin in Children and Adults With Fragile X Syndrome: an Open-label Study	Fragile X Syndrome	Drug: Metformin	Université de Sherbrooke	FRAXA Research Foundation	Unknown status	10 Years	40 Years	All	20	Phase 2	Canada
4	NCT03479476 (ClinicalTrials.gov)	April 30, 2018	20/3/2018	A Trial of Metformin in Individuals With Fragile X Syndrome	A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome	Fragile X Syndrome;Fragile X Mental Retardation Syndrome;Mental Retardation, X Linked;Genetic Diseases, X-Linked;Trinucleotide Repeat Expansion;Fra(X) Syndrome;Intellectual Disability;FXS;Neurobehavioral Manifestations;Sex Chromosome Disorders	Drug: Placebo Medication;Drug: Metformin	University of California, Davis	NULL	Recruiting	6 Years	25 Years	All	60	Phase 2;Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04141163
(ClinicalTrials.gov)

October 29, 2019

24/10/2019

Metformin in Patients With Fragile X

A Parallel Group Design Randomized Double-Blind Trial of Metformin Treatment in Patients With Fragile X Syndrome on Safety and Effects on Cognition, Anxiety, Attention and Biomarkers

Fragile X Syndrome

Drug: Metformin;Drug: Placebo oral tablet

Rowan University

FRAXA Research Foundation;University of Pennsylvania

Recruiting

18 Years

50 Years

Male

Phase 1;Phase 2

United States

NCT03862950
(ClinicalTrials.gov)

May 24, 2019

26/2/2019

A Trial of Metformin in Individuals With Fragile X Syndrome (Met)

A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)

Fragile X Syndrome;Fragile X Mental Retardation Syndrome;Mental Retardation, X-Linked;Genetic Diseases, X-Linked;Trinucleotide Repeat Expansion;Fra(X) Syndrome;Intellectual Disability;FXS;Neurobehavioral Manifestations;Sex Chromosome Disorders

Drug: Placebo Medication;Drug: Metformin

University of Alberta

St. Justine's Hospital

Recruiting

6 Years

25 Years

All

120

Phase 2

Canada

NCT03722290
(ClinicalTrials.gov)

September 1, 2018

24/10/2018

Metformin in Children and Adults With Fragile X Syndrome

Evaluate the Efficacy and Safety of Metformin in Children and Adults With Fragile X Syndrome: an Open-label Study

Fragile X Syndrome

Drug: Metformin

Université de Sherbrooke

FRAXA Research Foundation

Unknown status

10 Years

40 Years

All

Phase 2

Canada

NCT03479476
(ClinicalTrials.gov)

April 30, 2018

20/3/2018

A Trial of Metformin in Individuals With Fragile X Syndrome

A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome

Fragile X Syndrome;Fragile X Mental Retardation Syndrome;Mental Retardation, X Linked;Genetic Diseases, X-Linked;Trinucleotide Repeat Expansion;Fra(X) Syndrome;Intellectual Disability;FXS;Neurobehavioral Manifestations;Sex Chromosome Disorders

Drug: Placebo Medication;Drug: Metformin

University of California, Davis

NULL

Recruiting

6 Years

25 Years

All

Phase 2;Phase 3

United States